Guggenheim analyst Debjit Chattopadhyay raised the firm’s price target on NewAmsterdam Pharma (NAMS) to $41 from $35 and keeps a Buy rating on the shares. Compared to prior CETPi’s ...

New Amsterdam Pharma's obicetrapib shows promise as a best-in-class CETP inhibitor, successfully lowering LDL-C in Phase 3 trials, with potential for significant market impact. The company plans ...

17:07 EST NewAmsterdam Pharma (NAMS) files $500M mixed securities shelf See what stocks are receiving Strong Buy ratings from top-rated analysts. Filter, analyze, and streamline your search for ...

NewAmsterdam Pharma's obicetrapib shows promise in lipid management with successful Phase 3 trials, strong cash reserves, and a differentiated commercial strategy. Despite past CETP inhibitor ...

Shareholders of NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) will be pleased this week, given that the stock price is up 13% to US$20.91 following its latest full-year results. Revenues came in ...

Shareholders of NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) will be pleased this week, given that the stock price is up 13% to US$20.91 following its latest full-year results. Revenues came in 41% ...

On Thursday, Scotiabank (TSX:BNS) analyst George Farmer increased the price target on NewAmsterdam Pharma Co NV (NASDAQ: NAMS) shares to $52.00, up from the previous target of $47.00. The analyst ...

In the last three months, 7 analysts have published ratings on NewAmsterdam Pharma (NASDAQ:NAMS), offering a diverse range of perspectives from bullish to bearish. The following table encapsulates ...

Revenue: US$45.6m (up 223% from FY 2023). Net loss: US$241.6m (loss widened by 37% from FY 2023). US$2.56 loss per share (further deteriorated from US$2.15 loss in FY 2023). Revenue exceeded ...

NAARDEN, the Netherlands and MIAMI, Feb. 26, 2025 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a late-stage, clinical biopharmaceutical ...